Yukitake Jun, Otake Hiromi, Inoue Shigeki, Wakamatsu Kazumasa, Olivares Concepción, Solano Francisco, Hasegawa Katsutoshi, Ito Shosuke
Department of Clinical Immunology and Chemistry, Fujita Health University School of Health Sciences, Toyoake, Aichi 470-1192, Japan.
Melanoma Res. 2003 Dec;13(6):603-9. doi: 10.1097/00008390-200312000-00010.
Melanogenesis provides a unique target for the development of antitumour agents specific for malignant melanoma. Among the anti-melanoma compounds we have examined, 4-S-cysteaminylphenol (4-S-CAP), a phenolic amine, was found to have the most promising anti-melanoma effects. To further improve its efficacy as an anti-melanoma agent, we synthesized the R- and S-enantiomers (99% enantiomer excess) of alpha-methyl- 4-S-cysteaminylphenol (alpha-Me-4-S-CAP) and alpha-ethyl- 4-S-cysteaminylphenol (alpha-Et-4-S-CAP) by coupling 4-hydroxythiophenol with the oxazolines obtained from the (R)- and (S)-enantiomers of 2-amino-1-propanol and 2-amino-1-butanol, respectively. The enantiomers of alpha-Me-4-S-CAP and alpha-Et-4-S-CAP were found to be better substrates for tyrosinase than the natural substrate, L-tyrosine. In vitro experiments showed that all four enantiomers were highly cytotoxic to pigmented B16-F1 melanoma cells, the effect being 70-fold and 160-fold greater than that on non-pigmented B16-G4F melanoma cells and 3T3 fibroblasts, respectively. The cytotoxic effect against B16-F1 cells was completely inhibited by phenylthiourea, a tyrosinase inhibitor, or by N-acetyl-L-cysteine, which increases the intracellular reduced glutathione (GSH) level. 4-S-CAP and the enantiomers were taken up into B16-F1 cells at comparable rates, but showed varying rates of GSH depletion that were inversely correlated to the cytotoxicity. These results suggest that the use of enantiomers would increase the efficacy of tyrosinase-dependent cytotoxic phenols.
黑色素生成过程为开发针对恶性黑色素瘤的特异性抗肿瘤药物提供了一个独特靶点。在我们研究过的抗黑色素瘤化合物中,一种酚胺类化合物4-S-半胱氨酰苯酚(4-S-CAP)显示出最具前景的抗黑色素瘤效果。为进一步提高其作为抗黑色素瘤药物的疗效,我们通过将4-羟基硫酚分别与由2-氨基-1-丙醇和2-氨基-1-丁醇的(R)-和(S)-对映体得到的恶唑啉进行偶联,合成了α-甲基-4-S-半胱氨酰苯酚(α-Me-4-S-CAP)和α-乙基-4-S-半胱氨酰苯酚(α-Et-4-S-CAP)的R-和S-对映体(对映体过量99%)。结果发现,α-Me-4-S-CAP和α-Et-4-S-CAP的对映体比天然底物L-酪氨酸更是酪氨酸酶的优良底物。体外实验表明,所有这四种对映体对色素沉着的B16-F1黑色素瘤细胞均具有高度细胞毒性,其作用分别比未色素沉着的B16-G4F黑色素瘤细胞和3T3成纤维细胞高70倍和160倍。酪氨酸酶抑制剂苯硫脲或能提高细胞内还原型谷胱甘肽(GSH)水平的N-乙酰-L-半胱氨酸可完全抑制对B16-F1细胞的细胞毒性作用。4-S-CAP及其对映体以相当的速率被摄取到B16-F1细胞中,但显示出不同的GSH消耗速率,且该速率与细胞毒性呈负相关。这些结果表明,使用对映体将提高酪氨酸酶依赖性细胞毒性酚类药物的疗效。